Eron Kelly, CEO of ConcertAI, and Dr. Shaalan Beg, CMO, oncology, ConcertAI, discuss how AI can help physicians access the right information at the right time while supporting clinical trials, research, and quality initiatives.
|Articles|February 1, 2018
Ralf Otto Named COO at Rentschler Biopharma
Author(s)BioPharm International Editors
Biopharm industry veteran Ralf Otto named to lead development and manufacturing at Rentschler Biopharma.
Advertisement
Rentschler Biopharma, a contract development and manufacturing organization for biopharmaceuticals, appointed Ralf Otto as chief operating officer (COO), effective Feb. 1, 2018, succeeding Thomas Siklosi, who will move to Dr. Rentschler Holding GmbH & Co. KG, according to a Jan. 31, 2018 press statement.
Otto-who will be responsible for development, manufacturing, and quality management-has more than 20 years at senior positions in industry and management consulting and has overseen all stages of the biopharmaceutical value chain.
Most recently, he was a Partner at McKinsey & Company. Previously, he held executive positions in cell biology and biopharmaceutical manufacturing at Boehringer Ingelheim and as vice-president Biopharma Operations, Otto headed the Boehringer site in Fremont, CA.
Source:
Advertisement
Related to this article
Made Scientific's new 85,000-sq.-ft. facility, with 145 prior GMP batches, adds clinical- to commercial-scale cell therapy capacity.
mAbxience and Sandoz are targeting a $5.7 billion market with a proposed emicizumab biosimilar for hemophilia A.
Four cell therapy developers have pulled back from ex vivo manufacturing in the past month — ArsenalBio, TScan Therapeutics, and Cellectis all pivoted to in vivo approaches, while Bristol Myers Squibb terminated its manufacturing partnership with automation specialist Cellares after determining its platform couldn't meet requirements for commercial Breyanzi production, triggering layoffs.
Samsung Biologics signed a $262 million contract manufacturing agreement with an undisclosed European pharmaceutical company, extending production commitments through 2033 and lifting the CDMO's cumulative contract value past $21.9 billion.
FDA expands Winrevair’s label with HYPERION data, formalizes the use of non-animal testing methods, and Amgen reports positive Phase 3 results for dazodalibep in Sjögren disease.
The FDA has approved a label update for Merck's Winrevair (sotatercept-csrk) incorporating Phase 3 HYPERION data, showing a 76% reduction in clinical worsening events when added to background therapy in adults diagnosed with pulmonary arterial hypertension within the past year.
BIIE CEO Dr Stephen Wilson outlines rapid growth plans and a multidisciplinary technology stack targeting global clinical translation.
Advertisement
Advertisement